跳至主要内容
临床试验/CTRI/2021/05/033744
CTRI/2021/05/033744尚未招募未知

Pharmacokinetics of sulfobutylether-β-cyclodextrin (SBECD) and Remdesivir in patientswith severe COVID19 and kidney disease.

Department of nephrology0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Pms

入排标准

入选标准

  • 1. Patients with severe COVID19 and kidney disease [any one of the following â?? end stage kidney
  • disease OR acute kidney injury OR kidney transplant recipients with acute graft dysfuntion.
  • 2. Patients in whom the treating physician decides to start Remdesivir as a part of standard care.
  • 3. Willing to give written, informed consent.
  • 4. Participants of either gender
  • 5. Age >18 years

排除标准

  • 1. Patients with presumed or suspected diagnosis of COVID19
  • 2. Patients with pregnancy
  • 3. Patients with underlying liver disease [AST/ALT elevations > 5 times the upper limit of normal]
  • 4. Patients with any known allergy of reaction to Remdesivir.
  • 5. Patients requiring daily or more frequent dialysis sessions.
  • 6. Patients in the AKI or transplant catergory who require dialysis.

研究者

相似试验